Clinical Trials Outsourcing Market Share, Size, Trends, Industry Analysis Report, By End-Use (Pharmaceutical & Biotechnology Companies, Academic Institutes, Others); By Therapeutics Area; By Workflow; By Region; Segment Forecast, 2022 - 2030
The global clinical trials outsourcing market size is expected to reach USD 67.62 billion by 2030, according to a new study by Polaris Market Research. The report “Clinical Trials Outsourcing Market Share, Size, Trends, Industry Analysis Report, By End-Use (Pharmaceutical & Biotechnology Companies, Academic Institutes, Others); By Therapeutics Area; By Workflow; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Pharmaceutical and biotechnology businesses outsource clinical trials because they lack the requisite resources, experience, and time. Clinical trial outsourcing includes advantages such as lower costs, shorter turnaround times, and better results. Most clinical trials are contracted out to suppliers and contract research organisations.
The active pharmaceutical ingredients are used to create dosage forms, which are often created remotely from the locations where tablets, suspensions, and liquids are formed. As a result, more companies are outsourcing the manufacturing of API to countries with affordable labour. These factors contribute to the market need for clinical trials outsourcing on a global scale.
In the past decade, multinational pharmaceutical businesses have successfully established a variety of sourcing methods and service lines in emerging markets, either through local affiliates or service providers. Although these regions were originally given the task of hosting clinical trials in order to take advantage of their substantial patient population, developing markets now provide a wide range of highly qualified people that can support the entire clinical trial process programming, for example. In addition to data processing, scientific research, biostatistics, and regulatory operations were soon added to the list of activities that were outsourced.
Clinical trials conducted on-site have been disrupted globally as a result of the COVID-19 epidemic. During this time, there was a major overhaul of the healthcare sector. As a response, regulatory bodies all over the world have launched a range of initiatives targeted at accelerating clinical trials in order to find novel remedies.
Positive growth in demand for outsourced clinical trials was influenced by COVID-19. Numerous sectors, notably the healthcare sector, witnessed major transformation, and during COVID-19, small and medium-sized biotech enterprises were on the edge of closing permanently.
Clinical Trials Outsourcing Market Report Highlights
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook